Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study

Abstract

STEMI patients treated during the early experience with BVS had similar acute angiographic results as compared with the EES group. Clinical midterm follow-up data showed a higher clinical events rate compared with metal stents. The majority of clinical events occurred in the early phase after implantation and mainly in cases without post-dilatation. Optimisation of the implantation technique in the acute clinical setting is of paramount importance for optimal short and mid-term outcomes.

Long-term clinical results of biodegradable vascular scaffold ABSORB BVS™ using the PSP-technique in patients with acute coronary syndrome

“…1.3%, p = 0.05) [32]. Interestingly, the 30-day MACE rate in BVS patients without postdilatation was 6.8% and 3.6% in patients with post-dilatation.…”

Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography

“…Moreover, the ABSORB II trial demonstrated an ongoing risk of ScT through 3 years of 3% . In addition, increased incidence of ScT of up to 3% at 24 months follow‐up has been reported in patient cohorts reflecting daily clinical practice . The randomized AIDA trial, confirmed the increased risk of ScT in patient reflecting daily clinical practice, with 3.5% definite or probable device thrombosis in the Absorb arm and 0.9% in the Xience arm .…”

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions

“…In brief, the common inclusion criteria for this study are patients who had received a single BRS or CoCr EES that are 28 mm in length in long coronary lesions. The patients in the BRS group are selected from the BVS Expand [ 8 ] and BVS STEMI [ 9 ] registries which are single centre prospective observational registries conducted at Thorax Centre, Erasmus Medical Centre that evaluates the long term safety and performance of the BRS-absorb coronary stent in routine clinical practice post market registration. Informed, written consent was obtained from the patients before they undergo any procedure.…”